GLP-1 is a hormone your gut makes after a meal, a natural signal that food has arrived. It works on several organs at once, helping control blood sugar, slowing digestion, and turning down appetite in the brain. But your own GLP-1 lasts only moments in the blood, so the medicines built to copy it work by keeping that signal on far longer than your body ever would.1PubMed Central. Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions The idea for the first such drug came from an unlikely place: the venom of the Gila monster lizard.2PubMed. From Gila monster venom to dermatology: The history of glucagon-like peptide-1 receptor agonists
Where GLP-1 Comes From and What Triggers It
GLP-1 is made by scattered hormone-producing cells in the lining of the lower small intestine and the colon. They act like sensors, tasting what passes by and sending signals into the blood. GLP-1 rises within minutes of starting a meal and falls again between meals.
It belongs to a group called incretins, gut hormones that help the pancreas release more insulin after you eat than it would from blood sugar alone.3PubMed. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent In human small intestine tissue, sugar from food triggers GLP-1 release as it is pulled into the gut lining cells.4PubMed Central. Mechanisms Controlling Glucose-Induced GLP-1 Secretion in Human Small Intestine The artificial sweetener sucralose can also prompt some GLP-1 release in gut tissue, though real sugar acts through a different route.5PubMed Central. Mechanisms Controlling Glucose-Induced GLP-1 Secretion in Human Small Intestine
Release also follows a daily clock. In rats and mice, GLP-1 release peaks just before or at the start of the usual eating period.6PubMed. Circadian GLP-1 Secretion in Mice Is Dependent on the Intestinal Microbiome for Maintenance of Diurnal Metabolic Homeostasis In rats, the pancreas also responds more strongly to GLP-1 at that time than at the end of the eating period.7PubMed Central. Glucagon‐like peptide‐1: The missing link in the metabolic clock? Human pancreas cells exposed to melatonin overnight became more sensitive to GLP-1, which suggests people have a similar daily pattern.8PubMed Central. Glucagon‐like peptide‐1: The missing link in the metabolic clock?
This natural release is small and brief, tied to each meal. Medicines reach far higher, steadier levels than any meal produces.
How GLP-1 Lowers Blood Sugar
GLP-1 increases insulin from the pancreas only when blood sugar is raised.9PubMed Central. GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation The pancreas’s insulin-making cells release insulin when sugar metabolism inside them opens the way for calcium, and GLP-1 makes that sugar-driven step stronger.10PubMed Central. GLP-1: Molecular mechanisms and outcomes of a complex signaling system11PubMed Central. Molecular Physiology of Glucagon-Like Peptide-1 Insulin Secretagogue Action in Pancreatic β Cells
After a meal, insulin release gets a strong boost; when you’re fasting, the boost fades. So GLP-1 alone rarely drives blood sugar dangerously low, unlike some older diabetes pills (sulfonylureas) that force insulin out regardless of sugar. The picture changes when a GLP-1 medicine is combined with insulin or sulfonylureas, where low blood sugar becomes a real risk. That’s why doses of those other drugs are often adjusted, and why it helps to know the signs of low sugar: shakiness, sweating, and confusion.
Longer exposure does something different from a meal-time pulse. In rodent pancreas cells, 18 hours of steady GLP-1 receptor stimulation made the cells take up and burn more sugar and release more insulin.12PubMed Central. GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation
GLP-1 also lowers glucagon, the hormone that tells the liver to release stored sugar.13PubMed Central. The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice In human pancreas cells GLP-1 acts directly on glucagon-making cells, while in mice it works through a neighbouring hormone.14PubMed Central. The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice In type 2 diabetes glucagon often stays too high after meals, so cutting it lowers both after-meal and fasting sugar.
Slowing the Stomach
GLP-1 slows stomach emptying by acting on the vagus nerve, which links the gut and brain.15PubMed. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms In animals, cutting the nerve’s sensing fibres removed GLP-1’s effect on the stomach.16PubMed. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms GLP-1 can also dampen the nerve signals that drive stomach contractions.17PubMed Central. GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery Food then stays in the stomach longer, which smooths the after-meal rise in sugar and prolongs fullness. Some people get burping, bloating, or reflux, especially after rich or fatty meals, and large meals sit heavier because the stomach clears them more slowly. Eating slowly and stopping at the first sign of fullness eases these.
Delayed stomach emptying on GLP-1 medicines is a concern before surgery and heart procedures done under sedation.18PubMed Central. GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery The usual overnight fast may not empty the stomach on these drugs, and leftover food raises the risk of inhaling stomach contents under anesthesia, so teams may ask for a longer liquid-only period. It’s worth telling your surgical team that you take a GLP-1 medicine well before any procedure, since they may change fasting or dosing instructions.
How GLP-1 Quiets Hunger in the Brain
GLP-1 directly stimulates the brain’s “fullness” nerve cells in the hypothalamus, the brain’s appetite centre.19The Journal of Clinical Investigation. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss20PubMed Central. Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons It also indirectly quiets neighbouring “hunger” cells that drive eating.21The Journal of Clinical Investigation. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss In mice, switching on GLP-1-sensitive cells in this area sharply cut food intake.22PubMed Central. Activation of arcuate nucleus glucagon-like peptide-1 receptor-expressing neurons suppresses food intake
GLP-1 receptors also sit in the brain’s reward areas, which control wanting.23PubMed Central. Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review GLP-1 signalling reduces the dopamine surge triggered by cues like the sight or smell of food.24PubMed Central. Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review People with obesity on GLP-1 medicines report fewer food cravings, and brain scans show changed responses to tasty food.25PubMed Central. Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol
The drugs seem to lower the urge to seek food more than the pleasure of eating it. Many people describe “food noise,” the constant thoughts about food, going quiet. Meals can still taste good; the drive to keep eating fades.
A smaller appetite makes it easy to undereat protein. Putting protein and vegetables first at each meal helps. So does drinking fluids through the day, since thirst cues may also be blunted. Skipping meals entirely can worsen tiredness and nausea.
Why GLP-1 Medicines Cause Nausea
In animals, the brainstem area that receives gut signals is essential for GLP-1 medicines to cut food intake.26PubMed Central. The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP But 40 to 65% of the GLP-1-sensitive cells in one part of it respond mainly to nausea-type signals, while in another nearby area about 60 to 70% respond mainly to fullness signals.27PubMed Central. The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP The medicines activate both, which is why reduced appetite and queasiness often come together.
Nausea is most common when starting or after a dose increase. It often eases over weeks as the body adjusts, and slow dose increases are designed to limit it.
Avoiding greasy or very large meals usually helps. If vomiting stops you keeping fluids down, tell your prescriber, because dehydration can strain the kidneys. Severe, persistent belly pain needs prompt medical attention.
How the Medicines Differ From Your Own GLP-1
An enzyme found throughout the body, DPP-4, cuts natural GLP-1 so that its half-life in blood is about 1 minute.28PubMed Central. Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions DPP-4 blocking pills such as sitagliptin only stretch that to about 5 minutes.29PubMed Central. Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
The medicines, which your prescription may call GLP-1 receptor agonists, are modified versions of the hormone built to overcome its short life.30PubMed Central. Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy Changes at one end resist DPP-4, while an attached fat chain makes them cling to albumin, a blood protein, so they circulate much longer.31PubMed. Structural Overview of GLP-1 Analogs This design is what lets liraglutide work daily and semaglutide weekly.32PubMed. Structural Overview of GLP-1 Analogs The Gila monster’s exendin-4 shares about half its structure with human GLP-1 and naturally resists breakdown. It became the first such drug, exenatide.33PubMed. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent
Tirzepatide acts on GLP-1 receptors and also on the receptor for GIP, another gut incretin hormone.34PubMed Central. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist Giving both hormones together produced a bigger insulin response than either alone,35PubMed Central. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials and dual-acting drugs have shown greater effects on blood sugar and weight than GLP-1-only drugs.36PubMed Central. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Receptors don’t simply wear out under constant stimulation, though cells do pull GLP-1 receptors inside within minutes of strong stimulation, briefly dulling the response. Tirzepatide triggers this pull-in less than natural GLP-1 does,37PubMed Central. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist which may be part of why its insulin effect stays strong.
Effects on the Heart, Kidneys and Liver
GLP-1 receptors are found in the heart, blood vessel walls and immune cells, though at low levels.38PubMed Central. The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review39PubMed Central. Cardiovascular Benefits of GLP-1-Based Therapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control GLP-1 helps relax arteries, improving blood flow in people with and without diabetes.40PubMed Central. Cardiovascular Benefits of GLP-1-Based Therapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control In people with type 1 diabetes, a GLP-1 infusion lowered the lower blood pressure number.41PubMed Central. The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review GLP-1 medicines also reduce inflammation in vessel walls.42PubMed Central. The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review
In the kidneys, GLP-1 makes them release more sodium into the urine.43PubMed. Effects of GLP-1 in the kidney In healthy men a GLP-1 infusion raised sodium loss by 40% and lowered a blood-pressure-raising hormone by 19%.44The Journal of Clinical Endocrinology & Metabolism. Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men It did not change kidney filtering or blood pressure in that short test, and it briefly raised heart rate a little.45The Journal of Clinical Endocrinology & Metabolism. Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men A slightly faster pulse on these drugs is a known effect worth mentioning to your doctor.
In mice on a high-fat diet, GLP-1 drugs cut liver fat by up to about half and reversed fatty liver.46PubMed Central. GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice In people, adding exenatide to another fatty-liver drug reduced liver fat more than that drug alone.47PubMed Central. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Fat Loss Versus Muscle Loss
On semaglutide and tirzepatide, about three-quarters of lost weight is fat and roughly a quarter to 30% is lean mass, meaning muscle, organs and water.48PubMed Central. Muscle loss and GLP-1R agonists use Across studies, GLP-1 treatment cut fat mass by 17% and lean mass by only 2%.49PubMed Central. GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis Deep belly fat around the organs fell sharply.50PubMed Central. GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis That proportion mirrors diet-driven weight loss and is not unusually harmful unless strength or function declines.51PubMed Central. Muscle loss and GLP-1R agonists use What matters is strength and function, not lean tissue alone.52PubMed Central. Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans
To protect muscle, strength training two or three times a week helps, and so does eating protein at each meal despite a low appetite. Watch for real-world signs like trouble climbing stairs or rising from a chair. Older adults often have less muscle to spare and should be especially careful.
What Happens When You Stop
After stopping a GLP-1 medicine, weight returns fastest in the first months, then slows, levelling off around 60 weeks.53PubMed Central. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression A year after stopping, people regained on average about 60% of the weight they lost.54PubMed Central. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression The appetite suppression ends while the body’s own responses to weight loss, stronger hunger and slower calorie burning, persist.55PubMed Central. Early Weight Regain After GLP‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies Regain isn’t a personal failure; obesity is often treated as a long-term condition.
If you’re thinking of stopping, talk with your prescriber rather than quitting suddenly. Some plans lower doses gradually, though evidence on this is still developing. Keeping up the exercise and eating habits built during treatment may slow regain. In people with diabetes, blood sugar can rise again, so monitoring matters.
Alcohol, Cravings and the Brain
In animals, GLP-1 medicines reduced intake of alcohol and several drugs and lowered relapse-like behaviour.56PubMed Central. The potential role of GLP-1 receptor agonists in substance use disorders – a systematic review They act on the same reward areas that affect food craving.57PubMed Central. The potential role of GLP-1 receptor agonists in substance use disorders – a systematic review58PubMed Central. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders Human trials are still under way, so the drugs are not approved for addiction.59PubMed Central. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders
Alcohol on a slowed stomach and with low food intake may hit harder. Using the drug off-label for drinking isn’t advisable; discuss options with a doctor.
In animal models of brain disease, GLP-1 medicines calm the brain’s immune cells and cut inflammatory signals.60PubMed Central. GLP-1 receptor agonists in neurological diseases: mechanisms and therapeutic prospects from metabolism to neuroprotection Researchers are studying them for conditions like Alzheimer’s and Parkinson’s, but this remains unproven in people.